(S026) A Novel Method for Detecting Serious Cardiac Device Errors in Patients Receiving Radiotherapy Using Daily Pulse Checks

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

A novel method for monitoring CIEDs during radiotherapy is presented, which we report as effective, easy, and lacking adverse side effects. This simple technique is a cost-effective alternative to frequent device interrogations during the course of radiotherapy and allows for consistent daily monitoring.

Jonathan D. Grant, MD, Anne Dougherty, MD, Karimzad Kaveh, MD, Daniel R. Gomez, MD, Marc A. Rozner, PhD, MD; UT MD Anderson Cancer Center

INTRODUCTION: Little consensus exists for the proper monitoring of cardiac implantable electronic devices (CIEDs) in patients undergoing radiotherapy. We present data supporting a novel, easy, safe, and cost-effective method for detecting serious CIED problems arising during radiotherapy using daily heart rate (HR) monitoring.

MATERIALS AND METHODS: Since all CIEDs default to pacing at 60–72 beats per minute (bpm) without rate-response function (RRF) upon detection of a serious error, we instituted the following daily posttreatment pulse check protocol in 2010. Any patient who can be safely paced at a lower set rate of 75 bpm with RRF undergoes reprogramming at his preradiation CIED interrogation. Following each fraction of radiotherapy, these patients rest for 5 minutes and then undergo a pulse check. An HR of ≥ 74 bpm verifies the absence of a serious error. Because paroxysmal ventricular contractions may permit perfused pulses that register < 74 bpm, “tapping” on the CIED ensues to simulate patient exercise. An HR increase verifies the appropriate programming and the absence of a serious error. In a patient with an HR ≤ 73 and nonresponse to the tapping maneuver, a serious error is suspected, and a CIED interrogation is performed. At the completion of radiotherapy, device interrogation is performed for all patients, with return of the CIED to the appropriate settings.

RESULTS: Between February 2010 and October 2013, a total of 36 patients with CIEDs received treatment at the proton therapy center, 29 (81%) of whom were eligible for the pulse protocol. We found four patients (14%) with five serious CIED errors, manifested as a device parameter reset. A total of 845 fractions of radiotherapy were delivered in this cohort, giving an error rate per fraction of 0.6%. All affected patients were detected by a decrease in the measured HR of ≤ 73. No additional resets were discovered on any other device at routine posttreatment interrogation. No adverse events were experienced by any patient as a result of the increased lower pace rate. In one patient with HR < 74 bpm, the “tapping maneuver” confirmed the absence of a reset and prevented an unnecessary device interrogation.

CONCLUSIONS: A novel method for monitoring CIEDs during radiotherapy is presented, which we report as effective, easy, and lacking adverse side effects. This simple technique is a cost-effective alternative to frequent device interrogations during the course of radiotherapy and allows for consistent daily monitoring.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Related Content